+Compare
ONCT
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
19.05M

ONCT Oncternal Therapeutics Forecast, Technical & Fundamental Analysis

a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need.

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for ONCT with price predictions
08:00 PM EDT Sep 20, 2023

ONCT saw its Stochastic Oscillator leaves the overbought zone

The Stochastic Oscillator for ONCT moved out of overbought territory on September 20, 2023. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 37 similar instances where the indicator exited the overbought zone. In of the 37 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

ONCT moved below its 50-day moving average on August 16, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONCT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ONCT broke above its upper Bollinger Band on September 15, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ONCT entered a downward trend on September 18, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 12, 2023. You may want to consider a long position or call options on ONCT as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ONCT just turned positive on September 08, 2023. Looking at past instances where ONCT's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCT advanced for three days, in of 208 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.422) is normal, around the industry mean (22.643). P/E Ratio (0.000) is within average values for comparable stocks, (131.410). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.929). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (8.361) is also within normal values, averaging (308.526).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ONCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.21B. The market cap for tickers in the group ranges from 402 to 424.75B. NVO holds the highest valuation in this group at 424.75B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 32%. APLT experienced the highest price growth at 58%, while SEEL experienced the biggest fall at -80%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 11% and the average quarterly volume growth was 31%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 68
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

ONCT is expected to report earnings to fall 9.33% to -13 cents per share on November 09

Oncternal Therapeutics ONCT Stock Earnings Reports
Q3'23
Est.
$-0.14
Q2'23
Beat
by $0.01
Q1'23
Est.
$-0.20
Q4'22
Beat
by $0.01
Q3'22
Beat
by $0.03
The last earnings report on August 10 showed earnings per share of -15 cents, beating the estimate of -15 cents. With 8.40K shares outstanding, the current market capitalization sits at 19.05M.
A.I. Advisor
published General Information

General Information

a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
12230 El Camino Real
Phone
+1 858 434-1113
Employees
32
Web
https://www.oncternal.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CHMG40.050.34
+0.86%
Chemung Financial Corp
EPR41.76-1.00
-2.34%
EPR Properties
AKTX3.48-0.12
-3.35%
Akari Therapeutics plc
CBRE75.18-2.91
-3.73%
Cbre Group
NYMT8.46-0.59
-6.52%
New York Mortgage Trust

ONCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ONCT has been loosely correlated with ENLV. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ONCT jumps, then ENLV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ONCT
1D Price
Change %
ONCT100%
+2.17%
ENLV - ONCT
45%
Loosely correlated
-10.80%
VBIV - ONCT
44%
Loosely correlated
-10.64%
MDGL - ONCT
31%
Poorly correlated
-1.18%
CDTX - ONCT
30%
Poorly correlated
-10.96%
ARRY - ONCT
30%
Poorly correlated
-1.39%
More